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Background: Light-emitting diodes (LED) have been used to minimize muscle fatigue in athletes and healthy
subjects. Patients with chronic obstructive pulmonary disease (COPD) are susceptible to early muscle fatigue.
Objective: The objective of this study is to investigate the acute effects of LED on muscle function, exercise
capacity and cardiorespiratory responses during isometric and dynamic exercise in patients with COPD.
Methods: This study will assess 30 patients with moderate to severe obstruction (forced expiratory volume-one
second,FEV1 ≤70% predicted). Isometric and dynamic protocols will be conducted in two visits each, for a total of
four visits a week apart. First, venous blood will be taken from the patients. The isometric protocol will start with
the determination of the maximum voluntary isometric contraction (MIVC) to determine the workload (60% of
MIVC) for the isometric endurance test (IET). Patients will be randomized to receive either the placebo or LED
application (each point will be irradiated for 30 s and the energy received at each point will be 41.7 J). Immediately
after finishing this procedure, the patients will carry out the IET until the limit of tolerance or until a 20% fall of
strength is observed. After the test, another blood draw will be taken. In another visit (one week later), the same
order of procedures will be performed, except with the opposite (LED or placebo). For the dynamic endurance test
(DET), the same procedures described above will be followed, except with 75% of the maximal workload obtained
from the incremental cycle ergometer test used instead of the IET. The electromyography will be recorded during
the isometric and dynamic protocols. Differences in muscle function, exercise capacity and cardiorespiratory
responses between the LED and placebo applications will be analyzed. The therapeutic effects of LED could
minimize muscle fatigue in patients with COPD by increasing exercise tolerance.
Trial registration: Trial registration number: NCT01448564
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Chronic obstructive pulmonary disease (COPD) primar-
ily affects the lungs, but it is a systemic disease with
several extra-pulmonary manifestations, most notably
peripheral muscle dysfunction [1].
Skeletal muscle dysfunction in patients with COPD is
characterized by a reduction of muscle strength [2] and
endurance [3]. There is also a redistribution of muscle* Correspondence: simonedc@uninove.br
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reproduction in any medium, provided the orfiber types (low proportion of oxidative fibers and high
proportion of glycolytic fibers) [4,5], changes in the bio-
energetics (decrease of aerobic capacity, predominance
of glycolytic metabolism and rapid accumulation of
lactate) [6] and reduction of the capillary density and
capillary/fiber ratio [7,8]. These alterations, alone or
combined, are responsible for early muscle fatigue in
COPD patients.
Since peripheral muscle dysfunction is one of the most
serious systemic effects of COPD, strategies for improv-
ing muscle function are a priority in scientific research.
In this context, phototherapy is an electrophysical inter-
vention to be considered to prevent or postpone musclel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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recruitment of collateral circulation, increased supply of
oxygen and mitochondrial ATP level in the muscle [9].
Phototherapy by low-intensity laser and light-emitting
diodes (LED) is a non-thermal therapy [10] characterized
by a coherent and non-coherent beam of light, respect-
ively [11]. It has been shown that both the laser and
LED therapy produce similar effects due to the absorp-
tion of photons by chromophores in their tissue specific
wavelengths. Currently, the LED has been presented as
an alternative to the therapies that use low-intensity
laser due to its low cost and smaller size [12].
The effects of phototherapy promoted by LED are
mediated by the phenomenon of biostimulation [13]. In
brief words, biostimulation can be explained by the
absorption of energy by the intracellular chromophores
[14]. The light energy is converted into chemical energy
affecting positively several cellular biochemical processes
[10,14].
Skeletal muscle, a tissue with a high rate of aerobic
metabolism, is highly responsive to the stimulating
effects of phototherapy through infrared and red rays
[15]. Among the acute effects of the LED, the prevention
of muscular fatigue [16] and reduced levels of lactate
[17] stand out. Additionally, improvement in exercise
performance and attenuation of inflammatory biochem-
ical markers (creatine kinase, CK) and C-reactive protein
(CRP) [18] have been observed. In this context, this
study will investigate whether the positive effects, previ-
ously demonstrated in healthy individuals and athletes,
might occur in patients with COPD. Our hypothesis is
that the therapeutic effects of LED as vasodilation,Screened for 
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Figure 1 Flow of patients through the study.improves the collateral circulation, increasing the level
of oxygen content in tissues, and increased levels of
mitochondrial ATP [19] could minimize muscle fatigue,
increasing exercise tolerance in patients with COPD.
The primary aim of this study is to investigate the
acute effects of LED phototherapy on muscle function,
exercise capacity and cardiorespiratory responses during
isometric (60% of maximum voluntary contraction) and
dynamic (maximal incremental cycle ergometer test) ex-
ercises in patients with COPD. The secondary goal is to
assess the effects of LED phototherapy on biochemical
markers (CK, CRP and lactic acid).
Methods/Design
Study design
This study is a crossover, double blind (patient and
evaluator) and randomized trial. Randomization will be
performed to determine whether the patient will receive
LED or placebo (Figure 1). This study will be conducted
in the Exercise Physiology Laboratory at the Nove de
Julho University. This study was approved by the Ethics
Committee of our institution (11/451953) and registered
in Clinical Trials.gov NCT01448564 (2011-OCT-06).
The study will assess 35 patients with moderate to se-
vere obstruction (forced expiratory volume-one second
(FEV1) ≤70% predicted) and stable disease suggested by
the absence of any change in medication and symptoms
(increasing cough, increasing sputum volume and wors-
ening sputum purulence) in the four weeks before the
study. The exclusion criteria are oxygen-dependent pa-
tients, patients with orthopedic or neuromuscular disor-
ders, and dark-skinned patients. Dark-skinned patientsrecruitment
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content acts as competing chromophores. This protocol
was approved by the institutional ethics committee and
all patients will sign a written informed consent before
their participation in the study.
Outcome measures
The primary outcome for muscle function will be the
endurance time (sec) on cycling. The secondary out-
comes will be the slope coefficient from the regression
line between the median frequency and endurance time,
fatigue and dyspnea scores (from 0 to 10), and the levels
of CK (U/L), CRP (mg/dl) and lactate (mmol/L). In
addition, for the dynamic protocol, the maximum work-
load (watts), VO2 peak (L), ventilation (L), and heart rate
(bpm) variables will also be analyzed.
Assessment
Spirometry
Spirometry will be used to classify the severity of the ob-
struction and it will be performed at each visit before
the tests to ensure similar pulmonary function on the
different days. The tests will be performed using the
CPF-System (Medical Graphics Corporation®, St. Paul,
MN, USA) after administering a bronchodilator (400 μg
of inhaled salbutamol). The technical procedures,
acceptability and reproducibility criteria will follow the
recommendations of the Brazilian spirometry consensus
[20]. Values of forced vital capacity and forced expiratory
volume in the first secondwill be compared with those
predicted for the Brazilian population. The following
variables were recorded: FVC, FEV1, FEV1/FVC. The
data were expressed in absolute values (liters) and in
percentage of predicted (%) No, the correct sentence is
like that (percentage of predict)[21]. This test will take
approximately 20 minutes.
Skeletal muscle function assessment
The strength of the quadriceps femoris will be obtained
from the dominant leg by the maximal isometric volun-
tary contraction (MIVC). This measurement will be
made with the patients seated on a leg extension chair
(Carci®, São Paulo, Brazil) at 60° of knee flexion. A non-
elastic strap connecting the ankle to a load cell (EMG
System EMG800C, São José dos Campos, Brazil) will be
interfaced to a computer to record the MIVC. The force
will be expressed in Kgf. A strap will be placed across
the patient’s pelvis to minimize hip movement during
the tests. The patients will perform three repetitions of
MIVC of the knee extensors, each one maintained for
five seconds, with a one minute rest between them. The
highest value from the three reproducible contractions
(<5% variability among attempts) will be considered for
analysis, when the difference in strength of threecontractions exceeds 5%, another measure of MIVC will
be requested. The greatest value of these three contrac-
tions will be considered as the MIVC [22]. After a rest-
ing period of five minutes, the IET of the quadriceps
femoris will be evaluated by the isometric endurance
time at 60% of the MIVC until the limit of tolerance
(Tlim). The isometric endurance test will be finished
when a 20% drop of the produced force occurs. All mea-
surements will be performed with visual feedback on the
computer screen [22]. Dyspnea and leg fatigue will be
evaluated before and immediately after the test by the
modified Borg scale [23]. This test will take approxi-
mately 15 minutes.
Surface electromyography recording
Surface electromyography (sEMG) signals will be recorded
(EMG System, model EMG800C, Sao José dos Campos,
Brazil) during the MIVC, isometric endurance test, and
the incremental cycle ergometer test. The sEMG signals
will be recorded with a preamplifier (gain 1,000x) and
common mode rejection of more than −85 dB. The partic-
ipants’ skin will be prepared before the placement of the
EMG electrodes by shaving the hair at the site of the elec-
trode placement and cleaning the skin with alcohol [24].
Bipolar passive disposable dual Ag/AgCl snap elec-
trodes with a 1-cm diameter for each circular conductive
area and a 2-cm center-to-center spacing will be placed
over the longitudinal axes of the vastuslateralis. They
will be placed in the direction of the muscle fiber, taking
as reference two-thirds of the distance between the
anterior superior iliac spine and the lateral edge of the
patella [24]. Finally, a ground electrode will be put on
the left elbow.
The sampling frequency will be 2,000 Hz [25] and the
criterion adopted to normalize the EMG data will be the
MIVC. The digitized EMG data will first be band-pass
filtered at 20 to 400 Hz using a fourth order Butterworth
filter with a zero lag. For the temporal analysis, the amp-
litude of the EMG signals will be expressed as root mean
square (RMS) (1-s moving window) and normalized by
MIVC [26]. For the time-frequency analysis, the EMG
data will be analyzed with a short-time Fourier trans-
form applied to 1-s epochs [27]. The median frequency
of the spectrum for each epoch will be computed, and
the linear regression of the median frequencies versus
time will be determined. The slope of the straight line
(indicating the rate of frequency change per second) will
be adopted as a second index of fatigue [28-30]. All data
were analyzed using a customized program written in
Matlab (Mathworks Inc., Torrance, California, EUA).
Cardiopulmonary exercise testing
The maximal incremental cycle ergometer test will be
carried out on an electromagnetically braked cycle
Table 1 Settings for LED cluster
Number of LEDs 69 (34 red LEDs and 35 infrared LEDs)
Wavelength 660 nm (red) and 850 nm (infrared)
Frequency Continuous output
Optical output 10 mW (red) and 30 mW (infrared)
LED spot size 0.2 cm2 (for both), total spot sizes 13.8 cm2
Power density 0.05 W cm-2 (red) and 0.15 W cm-2 (infrared)
Energy 41.7 J (0.3 J from each red LED and 0.9 J
from each infrared LED)
Energy density 1.5 J cm-2 (red) and 4.5 J cm-2 (infrared)
Treatment time 30 s per point, 120 s (total treatment time for




4 points (isometric test) and 14 points
(dynamic test)
Total energy delivered 166.8 J (isometric test), 583.8 J (dynamic test)
Application mode Cluster held stationary to skin with slight
pressure at a 90° angle
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Groningen, The Netherlands) with gas exchange and
ventilatory variables being analyzed breath-by-breath
(Medical Graphics Corporation (MGC), St. Paul, MN,
USA). After 2 minutes at rest and more than 2 minutes
with a real “zero” workload obtained by a system that
moves the ergometer flywheel, the power (W) will be
continuously increased in a linear “ramp” pattern (5 to
15 W min-1) so that the incremental exercise test
duration will be between 8 and 12 minutes [29]. The
following data will be obtained breath-by-breath:
pulmonary oxygen uptake (VO2, mL min
-1), pulmonary
carbon dioxide production (VCO2, mL min
-1), minute
ventilation (VE, L min-1), tidal volume (VT, mL), re-
spiratory rate (f, respirations per minute); ventilatory
equivalent for O2 and CO2 (VE/VO2 and VE/VCO2, re-
spectively), and end tidal partial pressures of O2 and
CO2 (PETO2 and PETCO2, mmHg). ECG tracings and
heart rate (HR) will be recorded continuously and oxy-
gen pulse (VO2/HR) will be calculated. Arterial oxygen
saturation (SpO2) will be measured by pulse oximetry.
Blood pressure (BP) will be measured during every two
minutes of exercise. The average VO2 for the last 15 s of
the ramp will be considered representative of the sub-
ject’s peak VO2. Subjects will be asked to rate dyspnea
and leg fatigue at exercise cessation by using the modi-
fied Borg scale [23]. This test will take approximately 30
minutes.
Dynamic endurance testing
For the dynamic endurance test (DET), the same proce-
dures described above will be followed, except with 75%
of the maximal workload obtained from incremental
cycle ergometer test used instead of the IET. Patients
will perform this test until the limit of tolerance (Tlim).
Venous blood
Blood samples will be collected to measure the lactate
levels, as well as the activity of CK and CRP. To measure
these settings, a qualified nurse (blind to the group allo-
cation) will perform the asepsis of ventral side of the
arm. A blood sample will be collected prior to the appli-
cation of the LED or placebo and immediately after end-
ing the isometric endurance testing (Visits 1 and 2). The
same procedure will be performed at Visits 3 and 4 prior
to the application of the LED or placebo and after the
cycle ergometer testing. The samples will be analyzed
with infrared spectrophotometry via a spectrophotom-
eter (FEMTO® Industry and Trade of Instruments, São
Paulo, SP, Brazil) and specific kits for blood lactate ana-
lysis (Bioclin®, Belo Horizonte, Brazil) and CK analysis
(Labtest®, Lagoa Santa, Brazil). PCR analysis will be car-
ried out by the agglutination method using a specific
analysis kit (Wiener Laboratories®, Rosario, Argentina).LED
Patients will receive a single application of LED or
placebo on different days (a week apart). The LED or pla-
cebo will be administered immediately before the isomet-
ric and dynamic protocols. The radiation will be held
stationary with slight pressure of the LED cluster (THOR
Photomedicine®, London, UK) in contact with skin at an
angle of 90º. The application will be performed on two
points along the ventral side of the rectus femoris [31],
one point on the greater prominence of the muscle belly
of the vastuslateralis and vastusmedialis muscles. For the
isometric exercise protocol, the application will be
performed only on the right quadriceps femoris, while for
the dynamic exercise protocol, both lower limbs will re-
ceive the application on the four sites for the quadriceps
femoris, two sites for the hamstring muscle belly, and one
site in the center of the triceps surae [18]. Each point will
be irradiated for 30 s. The energy received at each point
will be 41.7 J. The irradiation settings are summarized in
Table 1.
For the placebo, the same procedures will be
performed but without irradiation. During the applica-
tion of the LED or placebo, the patient will use protect-
ive glasses that make it impossible to see whether there
is light being irradiated. This test will take approximately
five minutes.Protocol
In the first visit, patients undergo spirometry, maximum
voluntary isometric contraction (MIVC) and incremental
cycle ergometer test, one hour apart. The isometric and
dynamic endurance will be conducted in two visits each,
totaling four visits (a week apart) with the subjects
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group.
First, a venous blood sample will be taken from the
patients. The isometric endurance test (IET) will be
performed with 60% of MIVC. Then, patients will be
randomized to receive either a placebo or LED applica-
tion. Immediately after finishing this procedure, the
patients will carry out the IET until the limit of toler-
ance or a fall of 20% strength is observed. After the test,
another blood sample will be taken. During the next visit
(one week later), the same order of procedures will be
performed, except with the opposite application (LED or
placebo) that was applied at Visits 2 and3.
For the dynamic endurance test (DET), the same pro-
cedures described above will be followed, except with
75% of the maximal workload obtained from incremen-
tal cycle ergometer test used instead of the IET. A sum-
mary of the protocol can be visualized in Figure 2.
Statistical analysis
The sample size was calculated based on the primary
outcome, that is, endurance time. Assuming a Type 1
error rate of 0.05 and a Type 2 error rate of 0.2, with a
magnitude difference of 55 sec at the dynamic endur-
ance testing, a standard deviation of 79 sec [32], and a
hypothetical drop-out rate of 10%, 35 patients with



















Blood Collection Blood Collection 1 week
Figure 2 Schematic representation of the isometric and
dynamic protocols.differences between LED and placebo in the endurance
time. It will be used as the intention to treat analysis
with the baseline data being used for missing data from
patients who did not complete the whole protocol [33].
An additional analysis of the results involving only those
patients who complete the treatment originally allocated
will also be performed (per protocol analysis).
The normal distribution of data will be verified by the
Kolmogorov-Smirnov test. The parametric data will be
expressed by mean and standard deviation. The non-
parametric data will be expressed by median and inter-
quartile range. Differences in the variables of muscle
function, exercise capacity and cardiorespiratory re-
sponses between the LED and placebo treatments will
be compared with the paired Student’s t-test. Changes in
median frequency and root mean square will be analyzed
by repeated measures analysis of variance (basal, 25%,
50%, 75% and 100% of the endurance time) [34].
The linear regression analysis of the median frequency
versus endurance time will be performed to obtain the
slope coefficient of the straight line. For the correlations
between the electromyographic variables (median fre-
quency and root mean square) with endurance time,
peak workload at cycling, and biochemical markers (CK,
CRP and lactate). Pearson’s correlation will be used for
normal distributions and Spearman’s correlation will be
used for non-normal distributions. We used the
GraphPad Software, Inc., GraphPadInStat™(version 2.0)
La Jolla, CA, USAto calculate the sample size.
Discussion
Patients with COPD are susceptible to contractile fatigue
[35]due to poor muscle endurance [35], reduced muscu-
lar capillarization [36] and early onset of lactic acidosis
during exercise [37].
It is well known that fatigue and muscle injuries often
occur after high intensity exercise and are accompanied
by an inflammatory response. In this context, Leal
Júnioret al. [38] showed that phototherapy can delay the
onset of fatigue, probably by local mechanisms, including
minimizing oxidative stress. Studies have shown that in-
frared laser application before high-intensity exercise can
increase the removal of blood lactate and reduce muscle
damage, providing a faster muscle recovery [39,40].
The reasons for the increased blood lactate removal
and reduced muscular injuries after laser therapy are still
uncertain. A possible explanation is that the effects of
laser therapy occur by transforming light energy into
chemistry and propagating their effects to the tissues
and surrounding areas. The absorbed energy can act in
two ways: (i) stimulating the release of autacoid substances
(histamine, serotonin and bradykinin) and (ii) modifying
the normal enzymatic reactions, both in the sense of
excitement as inhibition [41].
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effects of laser therapy is the interaction of irradiated
photons with specific receptors in the mitochondria
causing an increase in mitochondrial function, along
with an increase in ATP (adenosine triphosphate), ribo-
nucleic acid (RNA) and protein synthesis. This inter-
action leads to an increase in oxygen consumption and
also in the ATP synthesis. Consequently, the photother-
apy increases the cellular metabolism and, thus, de-
creases the inflammatory process and lactate production
[11]. When absorbed by the tissues, the phototherapy
can cause changes in muscle activity because of changes
in the ion gradient [42], the concentration of ATP [43]
and activity of Na+K+-ATPase [44].
Muscle fatigue results in the inability to maintain the
metabolic process of muscle contraction. This can occur
due to reduced mitochondrial energy supply to the
muscle fibers. The explanation for the ability of the
phototherapy to decrease muscle fatigue is that it pro-
motes arteriolar vasodilation and improves peripheral
microcirculation [45]; consequently, there is an in-
creased supply of oxygen to muscle tissues.
The decrease in activity of the enzyme creatine kinase
(CK) after phototherapy could be related to a protective
effect of the phototherapy in the development of muscle
ischemia. There are some indications that the photother-
apy can reduce reactive oxygen species (ROS), while
antioxidant levels increase [46]. Moreover, as mentioned
earlier, laser therapy can stimulate the respiratory chain
and the synthesis of ATP [41]. These effects, in turn,
also contribute to a decrease in CK activity and the
reduction of blood lactate accumulation leading to
recovery from muscle fatigue [32,46-50]. Based on previ-
ous studies, phototherapy can be considered as a novel
and non-invasive treatment for reduction of muscle
fatigue induced by exercise in patients with COPD.
Trial status
This study protocol is registered with ClinicalTrials.gov
(NCT01448564) and this study is active, but is not yet
open for participant recruitment.
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